Part of the Cannabis Intelligence Briefing Series
The Flower report includes market-specific cultivation-demand data and projections to 2022, analysis of state and federal legislation, and insights into the rise of branded strains based on BDS Analytics’ GreenEdge™ Retail Sales Tracking Platform.
Additional key findings include:
- In California sales of branded flower saw a significant jump in share when new packaging rules came into play in July 2018. That month 41 percent of flower sales were branded, up from only 13.5 percent in June
- As happened earlier with edibles and concentrates, new lines of branded flower are constantly appearing, shrinking the combined share held by the top-five brands from 75.9 percent in 2014 to just 20.7 percent in the first half of 2018
- Despite the activity in flower brands, generic flower strains continue to dominate the market. Blue Dream continues to be the best-selling cannabis strain in most markets. In 2017 Blue Dream accounted for $12.5 million of Colorado flower sales
- The United States will constitute 85 percent of global demand while Canada will make up 10 percent in 2022; an estimated 61 percent of the demand will come from adult-use channels
- As with concentrates, the share of cultivation demand for processing into edibles will grow steadily as the category continues to gain share of consumer spending. In 2017, 143,902 pounds of raw flower were processed into edibles, up from 36,127 pounds in 2014. An estimated 360,844 pounds of raw flower will go into edibles in 2022 – a five-year CAGR of 20.2 percent
The 40-plus page report is available for $297 or as part of the Cannabis Intelligence Briefing Series subscription service from Arcview Market Research and BDS Analytics for $1,975.
*FULFILLMENT TAKES UP TO 1-2 BUSINESS DAYS